Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Rich Plasma and Stem Cell therapies improve orthopedic conditions

Although stem cells sounds innovative and cutting edge, this therapy has been around for quite some time. In today's advanced medical climate stem cells are being used to treat many orthopedic conditions including osteoarthritis of the hip knee and shoulder, partial tears of tendons, muscles, and ligaments including rotator cuff tears, and various back conditions including disc herniations.

19 Oct 2009

Lubricin injections can reduce cartilage degeneration

Medical researchers will report findings today (Oct. 19) that demonstrate that injecting the protein lubricin into knee joints can dramatically reduce cartilage degeneration.

19 Oct 2009

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, says study

Copper bracelets and magnetic wrist straps are ineffective in relieving arthritis pain, according to a new study led by a University of York academic.

19 Oct 2009

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead.

19 Oct 2009

Qforma introduces new phase of its healthcare database

Patients diagnosed with breast cancer or depression who are seeking a medical expert in their own community to guide them through treatment now have a place to start. Qforma, an advanced analytics and predictive modeling company, today introduced the new phase of its first-of-its-kind healthcare database "Most Influential Doctors," or MID, presented by USA TODAY.

19 Oct 2009

Genzyme ranked third on the global list for best employers

Genzyme Corporation announced today that scientists have again named the company a top employer in a survey ranking the reputations of biotechnology and pharmaceutical companies. Genzyme is ranked third on the global list of 575 companies, the second consecutive year it has achieved this position. Genzyme placed among the top 10 of all biotechnology and pharmaceutical companies in the world for the seventh year in a row.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Legendary coach helps raise awareness on osteoarthritis

After leading the U.S. men’s basketball team to Olympic gold last year and two weeks before the start of his 30th season as head coach of Duke University’s men’s basketball team, Mike Krzyzewski (Coach K), 61, is teaming up with the Arthritis Foundation to help raise awareness of the disease that nearly ended his coaching career 10 years ago.

13 Oct 2009

QRxPharma signs contractual agreement with Patheon

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today a contractual agreement with Patheon to manufacture clinical supplies of QRxPharma's controlled release Dual-Opioid(TM) formulation (MoxDuo(TM)CR). MoxDuo(TM)CR is designed to provide 12 hours of pain relief in patients suffering from moderate to severe chronic pain (including cancer, lower back, osteoarthritis and neuropathic).

12 Oct 2009

Doctors and scientists form national pain research centre

An expert network of doctors and research scientists is forming the world's first national centre for research into understanding pain in arthritis. Backed by medical research charity the Arthritis Research Campaign and The University of Nottingham, it will aim to improve treatments for arthritis - the most common cause of chronic pain - which affects more than ten million people in the UK.

12 Oct 2009

Electrostimulation techniques for osteoarthritis still unclear

Despite twenty years of research on the use of electrostimulation techniques (TENS) for treatment of osteoarthritis in the knee, researchers still cannot say whether it reduces pain or physical disability. This is the conclusion of a Cochrane Systematic Review of electrostimulation trials in osteoarthritis

7 Oct 2009

Opioid drugs may not be effective for osteoarthritis

Should you take opioid drugs for hip and knee pain caused by osteoarthritis? Probably not, suggests a new review of the best research on the subject.

7 Oct 2009

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced positive top-line clinical results for its lead pain drug Ketotransdel®( )in a Phase 3 trial which evaluated the efficacy and safety of the drug in acute soft tissue injuries of the upper and lower extremities.

6 Oct 2009

Biochemics signs research collaboration agreement with Unilever

BioChemics, Inc. a company “enhancing drug delivery through biophysical modulation,” is pleased to announce the signing of a research collaboration agreement with Unilever, one of the world’s largest consumer goods companies, to utilize BioChemics’ proprietary topical delivery technology for the delivery of Unilever’s compounds.

5 Oct 2009

CIHR and CMAJ honour eight Canadian Health Researchers

The Canadian Institutes of Health Research (CIHR) and the Canadian Medical Association Journal (CMAJ) today honoured eight outstanding Canadian individuals and teams with the first ever CIHR-CMAJ Top Canadian Achievements in Health Research Awards, which recognize and celebrate Canadian health research and innovation excellence.

29 Sep 2009

Leptin can determine osteoarthritis in obese patients

The link between obesity and osteoarthritis may be more than just the wear and tear on the skeleton caused by added weight.

29 Sep 2009

Obesity due to leptin deficiency plays major role in knee osteoarthritis

In 2005 the World Health Organization (WHO) estimated that globally 400 million adults were obese, defined by a body mass index (BMI) of 30 kg/m2 or greater. WHO projects that by 2015 there will be more than 700 million obese adults worldwide. Obesity is considered to be one of the greatest risk factors for osteoarthritis, a progressive musculoskeletal disorder that is characterized by loss of joint cartilage.

29 Sep 2009

Current stem cell applications to be discussed at NJIT

Stem cell researcher Treena Livingston Arinzeh will discuss current stem cell applications at NJIT, including the regeneration of bone and cartilage for bone fracture and osteoarthritis treatments, spinal cord repair, and liver regeneration at NJIT's first Research Caf.

25 Sep 2009

NDA submitted to the FDA for new osteoarthritis drug

NicOx S.A. today announced that a New Drug Application (NDA) for naproxcinod has been submitted to the United States Food and Drug Administration (FDA), seeking approval for an indication for the relief of the signs and symptoms of osteoarthritis (OA). The NDA file contains data from three large pivotal phase 3 studies, all of which met their co-primary efficacy endpoints. NicOx plans to submit a Marketing Authorization Application (MAA) for naproxcinod to the European Medicines Agency (EMEA) in Q4 2009.

25 Sep 2009

NicOx announces publication of blood pressure results from the phase 3 study of naproxcinod

NicOx S.A. (NYSE Euronext Paris: COX) today announced that an important scientific article has been published in the September issue of the American Journal of Cardiology. The publication describes the blood pressure results from the 301 phase 3 study for naproxcinod in detail. Naproxcinod is the first-in-class Cyclooxygenase-Inhibiting Nitric Oxide Donating (CINOD) anti-inflammatory agent for the relief of the signs and symptoms of osteoarthritis (OA).

22 Sep 2009